Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
My locations
Active clinical trials
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in…
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
My research
Top areas of exploration
- alpha 1-Antitrypsin Deficiency , 9 publications
- Pulmonary Disease, Chronic Obstructive , 8 publications
- alpha 1-Antitrypsin , 7 publications
- Phenotype , 3 publications
Research activity
Search our accepted insurances list
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
My areas of focus
Stories and news
Eyes on the Prize: Progress in Cystic Fibrosis Research Amidst a Pandemic
Just over one year ago, COVID-19 exploded on news headlines — putting the world in a tizzy about what this new virus was, who was at risk and how to prevent…
Changing the Narrative of Cystic Fibrosis
There was once a time where cystic fibrosis, or CF, was considered a terminal disease. While this may have been the case years ago, patients diagnosed with CF…
